Charles River Laboratories Intl. Inc vs Starbucks Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $303.31 (market cap $14.23B), while Starbucks Corp trades at $92.51 (market cap $106.26B). The key difference: Starbucks Corp is far larger — about 7.5× Charles River Laboratories Intl. Inc's market cap, and Starbucks Corp pays a 2.7% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Starbucks Corp for 190 Days on average.
| CRL | SBUX | |
|---|---|---|
Market Cap | $14.23B | $106.26B |
Volume | 1,176,885 | 30,248,434 |
Sector | Health | Consumer Cyclical |
52-Week High | $310.77 | $108.55 |
52-Week Low | $149.93 | $78.46 |
Typical Hold Time | 33 Days | 190 Days |
Enterprise Value | $17.06B | $125.08B |
Dividend Yield | — | 2.7% |
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
Starbucks (SBUX) trades at $91.66, down 2.05% amid a bearish technical outlook with support at $89 and resistance at $92. The company reported mixed quarterly results with Q2 2026 EPS beating expectations at $0.85 vs. $0.66, but Q4 2025 missed at $0.56. Recent news highlights store closures and restructuring charges of approximately $300 million as part of a strategic turnaround. Revenue growth remains modest at $37.18B for 2025, with net income margin at 5.17%.
The stock presents a cautious opportunity with analyst consensus price target of $115.50 implying 26% upside, though high P/E of 53.88 raises valuation concerns. Key risks include execution of store optimization, labor relations, and geopolitical tensions in China. Institutional sentiment is divided with 47% buy ratings, but technical indicators signal near-term pressure.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →